Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Introduction of PHiD-CV (Pneumococcal Nontypeable H. Influenza Protein D-conjugate Vaccine) for Nunavik Children, Quebec, Canada

NCT01694329 is registered in ClinicalTrials.gov with CHU de Quebec-Universite Laval as lead sponsor.

NCT NCT01694329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01694329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Introduction of PHiD-CV (Pneumococcal Nontypeable H. Influenza Protein D-conjugate Vaccine) for Nunavik Children, Quebec, Canada
Lead sponsor
CHU de Quebec-Universite Laval
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2012
Completion date
December 31, 2017
Enrollment
1,420 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lower respiratory tract infection, acute upper respiratory infection, invasive pneumococcal disease, protection against, otitis media (om)